Standardizing your Dry Eye Screening with the Visionix VX120+ ; Patty Barkey, COE

Поділитися
Вставка
  • Опубліковано 20 вер 2020
  • ​As eye care move towards a world that has propelled into change because of the COVID-19 crisis, more ECPs are looking into new ways to evolve their practice and put technology to work to enhance the patient experience.
    Patti Barkey, the director of Dry Eye University, shares her experience with helping practice owners provide solution for “dry eye disease”. Clinicians will be introduced to a new solution for Dry Eye screening.
    Practices with a medical model in place can screen for dry eye and so much more, to provide the best surgical outcomes for patients. This webinar explores the practical application of the Visionix® VX120+ multi-modal anterior segment analyzer to standardize your practice with dry eye screening.
    Attendees of this course will:
    • Understand how Dry Eye screening can improve outcomes and increase revenue,
    • Understand the benefits of multi-modal anterior segment analysis using one single unit,
    • Explore the unique benefits of implementing a Visionix® VX120+ with dry eye screening.
    This webinar is ideal for practice owners who are looking for new ways to transform their eye care practice, furnishing a “cold open”, or boutique clinics exploring new ways to expand services.
    About the featured technology:
    Luneau Technology’s Visionix® VX120+ is ideal for boutique eye care practices and is specifically designed to help ECPs enhance the experience of patients with Ocular Surface disease symptoms. It offers wavefront-based technology with all the essentials in vision screening (Scheimpflug tomography, Shack-Hartmann wavefront aberrometry, Placido Ring corneal topography, etc.) in a single unit. It is remote-ready and ideal for high-volume, multi-location clinics, or a telehealth set-up.
    --
    ODwire.org: The Largest Online Community Exclusively for ECPs.
    Always Free * Always Fun!
    www.odwire.org
  • Наука та технологія

КОМЕНТАРІ •